Catalyst Pharmaceuticals, Inc.【CPRX】 業績推移・財務諸表

機能の使い方
(単位:千ドル) 2Q11 3Q11 4Q11 1Q12 2Q12 3Q12 4Q12 1Q13 2Q13 3Q13 4Q13 1Q14 2Q14 3Q14 4Q14 1Q15 2Q15 3Q15 4Q15 1Q16 2Q16 3Q16 4Q16 1Q17 2Q17 3Q17 4Q17 1Q18 2Q18 3Q18 4Q18 1Q19 2Q19 3Q19 4Q19 1Q20 2Q20 3Q20 4Q20 1Q21 2Q21 3Q21 4Q21 1Q22 2Q22 3Q22 4Q22 1Q23 2Q23 3Q23 4Q23 1Q24 2Q24 3Q24 4Q24 1Q25 2Q25 3Q25 4Q25
売上高 - - - - - - - - - - - - - - 0 - - - 0 - - - 0 - - - 0 - - - 500 12,448 28,837 30,897 30,122 29,136 29,604 29,316 30,682 30,205 36,365 35,954 38,309 43,089 53,113 57,244 60,757 85,366 99,582 102,688 110,568 98,509 122,710 128,695 141,820 141,421 146,563 148,392 152,613
売上成長率(%) - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 28.3 43.6 19.4 15.3 7.6
売上原価 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1,711 4,261 4,387 4,398 4,150 4,139 3,878 4,869 4,681 4,545 5,310 7,348 5,890 7,643 9,665 11,195 9,946 12,045 14,167 15,809 12,520 15,405 19,277 21,643 17,911 20,614 22,654 26,074
研究開発費 905 614 960 727 532 654 26,388 1,092 2,132 2,804 30,371 2,748 2,098 2,885 2,384 - - - - - - - - - - 2,704 3,404 3,259 3,704 4,538 8,416 3,307 4,629 4,597 6,308 4,222 4,349 3,749 4,175 3,007 4,450 4,487 4,992 3,403 3,983 8,310 4,093 3,562 3,954 83,662 1,972 2,581 2,985 3,284 3,798 3,887 4,358 2,657 1,807
販売管理費 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 8,416 8,987 8,067 11,409 10,063 10,833 9,984 13,352 12,716 11,532 12,153 13,227 16,430 12,918 14,167 14,668 29,718 28,396 33,560 42,036 46,938 40,730 45,880 44,192 46,911 45,949 47,470 53,421
営業利益率 (%) - - - - - - - - - - - - - - - - - - - - - - - - - - 44.3 44.8 45.2 44.7 40.5
営業利益 -1,398 -1,132 -2,035 -1,365 -1,068 -1,284 -1,506 -1,706 -2,654 -3,246 -2,707 -3,509 -2,991 -4,110 -3,984 - - - -6,192 - - - -4,315 - - -4,307 -5,512 -5,934 -6,336 -8,183 -14,844 -988 10,959 13,845 8,006 10,699 10,281 11,703 8,617 9,801 15,838 14,004 12,742 17,366 28,569 25,102 30,801 35,609 46,699 -37,188 41,692 27,126 54,246 50,909 62,843 63,367 66,298 66,267 61,846
営業費用 1,397 1,131 35,701 1,364 1,067 1,283 41,254 1,705 2,653 3,245 -42,264 3,508 2,990 4,109 3,983 - - - - - - - - - - 4,306 5,511 5,933 6,335 8,182 15,343 13,436 17,878 - - - - - - - - - - - - - - - - - - - - - - - - - -
経常(税引前)利益 -1,395 -1,128 -34,064 -1,090 -290 -2,622 -38,180 -1,745 -3,144 -5,913 40,824 -3,812 -3,199 -5,010 -3,491 - - - - - - - - - - -4,178 -5,388 -5,700 -5,966 -7,839 -14,500 -645 11,409 14,238 8,405 11,035 10,393 11,737 8,723 9,882 15,900 14,072 12,813 17,459 28,245 26,007 33,008 37,313 48,512 -38,021 46,707 29,089 55,788 57,205 74,181 71,286 69,293 71,035 71,901
経常(税引前)利益率(%) - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -2899.9 -5.2 39.6 46.1 27.9 37.9 35.1 40.0 28.4 32.7 43.7 39.1 33.4 40.5 53.2 45.4 54.3 43.7 48.7 -37.0 42.2 29.5 45.5 44.5 52.3 50.4 47.3 47.9 47.1
法人税等合計 - - - - - - - - - - - - 0 - - - - - - - - - - - - 0 - 0 0 0 - 0 449 608 475 609 613 -31,603 -2,714 2,219 3,719 3,743 3,504 4,218 6,626 3,259 7,537 7,745 10,750 -7,257 11,863 5,814 14,994 13,321 18,245 14,549 17,185 18,252 19,203
実効税率(%) - - - - - - - - - - - - - - - - - - - - - - - - - - 24.6 20.4 24.8 25.7 26.7
純利益 -1,395 -1,128 -2,352 -1,090 -290 -2,622 -77 -1,745 -3,144 -5,913 -1,355 -3,812 -3,199 -5,010 -3,491 -5,411 -4,559 -4,450 -5,816 -5,387 -4,569 -3,954 -4,164 -4,968 -3,880 -4,178 -5,388 -5,700 -5,966 -7,839 -14,500 -645 10,959 13,630 7,929 10,426 9,779 43,339 11,437 7,663 12,181 10,329 9,309 13,241 21,619 22,748 25,471 29,568 37,762 -30,764 34,844 23,275 40,794 43,884 55,936 56,737 52,108 52,783 52,698
純利益率(%) - - - - - - - - - - - - - - - - - - - - - - - - - - 39.4 40.1 35.6 35.6 34.5
一株あたり利益 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 0.11 0.13 0.08 0.1 0.09 0.42 0.11 0.07 0.12 0.1 0.09 0.13 0.21 0.22 0.24 0.28 0.36 -0.29 0.33 0.2 0.35 0.37 0.46 0.47 0.43 0.43 0.43
希薄化後一株あたり利益 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 0.1 0.13 0.07 0.1 0.09 0.41 0.11 0.07 0.11 0.1 0.09 0.12 0.2 0.2 0.23 0.26 0.33 -0.29 0.31 0.19 0.33 0.35 0.44 0.45 0.41 0.42 0.41
EBITDA - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -